| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 |
| Sales | 4,660 | 4,830 | 3,330 | 15,620 | 17,390 |
| Sales Growth | -3.52% | +45.05% | -78.68% | -10.18% | +47.75% |
| Net Income | -109,740 | 27,780 | -65,700 | -50,360 | -60,560 |
| Net Income Growth | -495.03% | +142.28% | -30.46% | +16.84% | -1,111.02% |
Puretech Health Plc ADR (PRTC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
PureTech Health plc is a clinical-stage biotherapeutics company. It engages in discovering, developing and commercializing medicines for devastating diseases, including inflammatory and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. PureTech Health plc is based in Boston, Massachusetts.
Fiscal Year End Date: 12/31